- Management of Crohn's disease
Management of Crohn's disease involves first treating the acute symptoms of the disease, then maintaining remission. Treatment initially involves the use of medications to eliminate infections, generally antibiotics, and reduce inflammation, generally aminosalicylate anti-inflammatory drugs and corticosteroids. Surgery may be required for complications such as obstructions or abscesses, or if the disease does not respond to drugs within a reasonable time.
Once remission is induced, the goal of treatment becomes maintenance of remission, avoiding the return of active disease, or "flares". Because of side-effects, the prolonged use of corticosteroids is avoided. Although some people are able to maintain remission with aminosalicylates alone, many require immunosuppressive drugs.
Aminosalicylate anti-inflammatory drugs
5-aminosalicylates (5-ASA) include the following:
- Mesalazine or mesalamine, which is marketed in the forms Lialda, Asacol, Pentasa, Salofalk, Dipentum and Rowasa.
- Sulfasalazine, which is converted to 5-ASA and sulfapyridine by intestinal bacteria. The sulfapyridine may have some therapeutic effect in rheumatoid arthritis. However, the sulfapyridine component is often the limiting factor in treatment of Crohn's disease because of high side-effect profile.
5-ASA compounds have been shown to be useful in the treatment of mild-to-moderate Crohn's disease. They are usually considered to be first line therapy for disease in the ileum and right side of the colon particularly due to their lower side effect profile compared to corticosteroids.
Corticosteroid anti-inflammatory drugs
Corticosteroids are a class of anti-inflammatory drug that are used primarily for treatment of moderate to severe flares of Crohn's disease. They are used more sparingly due to the availability of effective treatments with fewer side-effects. The side effects of corticosteroids include Cushing's syndrome, mania, insomnia, hypertension, high blood glucose, osteoporosis, and avascular necrosis of long bones. These should not be confused with the anabolic steroids used to enhance athletic performance.
The most commonly prescribed oral steroid is prednisone, which is typically dosed at 0.5 mg/kg for induction of remission. Intravenous steroids are used for cases refractory to oral steroids, or where oral steroids cannot be taken. These are administered in the hospital setting. Because corticosteroids reduce the ability to fight infection, care must be used to ensure that there is no active infection, particularly an intra-abdominal abscess before the initiation of steroids.
Budesonide is an oral corticosteroid with limited absorption and high level of first-pass metabolism, meaning that less quantities of steroid enter into the bloodstream. It has been shown to be useful in the treatment of mild-to-moderate Crohn's disease and for maintenance of remission in Crohn's disease. Formulated as Entocort, budesonide is released in the ileum and right colon, and is therefore has a topical effect against disease in that area.
Steroid enemas can also be used for disease of the lower colon and rectum, in order to treat symptoms. Hydrocortisone and budesonide liquid and foam enemas are being marketed for these reasons.
Corticosteroids however have a host of side effects, some very serious, and it is desirable to curtail their use whenever possible.
Mercaptopurine immunosuppressing drugs
Azathioprine and 6-mercaptopurine (6-MP) are the most used immunosuppressants for maintenance therapy of Crohn's disease. They are purine anti-metabolites, meaning that they interfere with the synthesis of purines required for inflammatory cells. They have a duration of action of months, making it unwieldy to use them for induction of remission. Both drugs are dosed at 1.5 to 2.5 mg/kg, with literature supporting the use of higher doses.
Azathioprine and 6-MP have been found to be useful for the following indications:
- For maintenance therapy for people who are dependent on steroids.
- Fistulizing disease.
- Induction of remission in steroid refractory disease.
- Maintenance of remission after surgery for Crohn's disease.
Tumor Necrosis Factor Inhibitors
Infliximab, marketed as Remicade, is a mouse-human chimeric antibody that targets tumour necrosis factor, a cytokine in the inflammatory response. It is a monoclonal antibody that inhibits the pro-inflammatory cytokine tumour necrosis factor alpha. It is administered intravenously and dosed per weight starting at 5 mg/kg and increasing according to character of disease.
Infliximab has found utility as follows:
- Maintenance of remission for people with Crohn's disease.
- Induction of remission for people with Crohn's disease.
- Maintenance for fistulizing Crohn's disease.
Side effects of infliximab, like other immunosuppressants of the TNF class, can be serious and potentially fatal, and infliximab carries an FDA black-box warning on the label. Listed side effects include hypersensitivity and allergic reactions, risk of re-activation of tuberculosis, serum sickness, and risk of multiple sclerosis. Serious side effect also include lymphoma and severe infections, including progressive multifocal leukoencephalopathy (PML) an opportunistic viral infection of the brain that can cause death.
Adalimumab, marketed as Humira, like infliximab is an antibody that targets tumour necrosis factor. Adalimumab has been shown to reduce the signs and symptoms of, and is approved for treatment of, moderate to severe Crohn’s disease (CD) in adults who have not responded well to conventional treatments and who have lost response to, or are unable to tolerate infliximab.
Adalimumab also has a number of serious, potentially fatal, safety concerns characteristic of the anti-TNFα drugs. It too has a black box warning on its FDA label. Listed potential side effects include serious and sometimes fatal blood disorders; serious infections including include TB (tuberculosis) and infections caused by viruses, fungi, or bacteria; rare reports of lymphoma and solid tissue cancers; rare reports of serious liver injury; and rare reports of demyelinating central nervous system disorders); and rare reports of cardiac failure.
Natalizumab, marketed as Tysabri, is an anti-integrin monoclonal antibody that has shown utility as induction and maintenance treatment for moderate to severe Crohn's disease. Natalizumab may be appropriate in patients who do not respond to medications that block tumor necrosis factor-alpha such as infliximab.
In January 2008, the FDA approved natalizumab for both induction of remission and maintenance of remission for moderate to severe Crohn's disease.
A total of 3 large randomized controlled trials have demonstrated that natalizumab is effective in increasing rates of remission and maintaining symptom-free status in patients with Crohn's disease.
Like infliximab, natalizumab has also been linked to PML (though only when used in combination with interferon beta-1a). The label also recommends monitoring of liver enzymes due to conerns over possible damage or failure.
Also associated with a rare but serious risk of multifocal leukoencephalopathy (brain infection leading to death or severe disability). Therefore a specific program exists in which prescribers muct be enrolled, CD-TOUCH (Crohn's Disease-Tysabri Outreach Unified Commitment to Health) Prescribing Program.
Surgery is normally reserved for complications of Crohn's disease or when disease that resists treatment with drugs is confined to one location that can be removed. Surgery is often used to manage complications of Crohn's disease, including fistulae, small bowel obstruction, colon cancer, small intestine cancer and fibrostenotic strictures, when strictureplasty (expansion of the stricture) is sometimes performed. Otherwise, and for other complications, resection and anastomosis - the removal of the affected section of intestine and the rejoining of the healthy sections - is the surgery usually performed for Crohn's disease (e.g., ileocolonic resection). Neither type of surgery cures Crohn's disease, as recurrence often reappears in previously unaffected areas of the intestine.
Diet and lifestyle
Many diets have been proposed for treatment of Crohn's disease, and many do improve symptoms, but none have been proven to actually cure Crohn's disease. Specific Carbohydrate Diet usually needs adjustments for patients so that they can handle the diet. If a patient finds that certain foods increase or decrease the symptoms, then they may adjust their diet accordingly. A food diary is recommended to see what positive or negative effects particular foods have. A low residue diet may be used to reduce the volume of stools excreted daily. People with lactose intolerance due to small bowel disease may benefit from avoiding lactose-containing foods. Patients who cannot eat are recommended to take total parenteral nutrition (TPN) - a source of vitamins and nutrients.
Because the terminal ileum is the most common site of involvement and is the site for vitamin B12 absorption, people with Crohn's disease are at risk for B12 deficiency and may need supplementation. In cases with extensive small intestine involvement, the fat soluble vitamins A, D, E and K can be deficient. Folate deficiency is a risk when being treated with methotrexate.
Stress can influence the course of Crohn's disease. Conversely, stress is likely to be caused by the flaring up of the disease and this would make day to day life more difficult.
Smoking has also been noted to have an association with Crohn's, and smokers with Crohn's are encouraged to quit.
In an experimental idea called Helminthic therapy, moderate hookworm infections have been demonstrated to have beneficial effects on hosts suffering from diseases linked to overactive immune systems. This is possibly explained by the hygiene hypothesis. Helminthic therapy may help sufferers of Crohn's Disease Hookworm therapy is currently in the trial stage at the University of Nottingham. Due to the unconventional nature of this therapy, it is not widely used.
Complementary and alternative medicine
More than half of Crohn's disease sufferers have tried complementary or alternative therapy. These include diets, probiotics, fish oil and other herbal and nutritional supplements. The benefit of these medications is uncertain.
Acupuncture is used to treat inflammatory bowel disease in China, and is being used more frequently in Western society. There is evidence that acupuncture has benefits beyond the placebo effect, improving quality of life, general well-being and a small decrease in blood-bound inflammatory markers.
- Boswellia is an ayurvedic (Indian traditional medicine) herb, used as a natural alternative to drugs. One study has found that the effectiveness of H-15 extract is not inferior to mesalazine: "Considering both safety and efficacy of Boswellia serrata extract H15 it appears to be superior over mesalazine in terms of a benefit-risk-evaluation."
- Methotrexate is a folate anti-metabolite drug which is also used for chemotherapy. It is useful in maintenance of remission for those no longer taking corticosteroids.
- Metronidazole and ciprofloxacin are antibiotics which are used to treat Crohn's that have colonic or perianal involvement, although this use has not been approved by the Food and Drug Administration. They are also used for treatment of complications, including abscesses and other infections accompanying Crohn's disease.
- Thalidomide has shown response in reversing endoscopic evidence of disease.
- Cannabis may be used to treat Crohn's Disease with its anti-inflammatory properties. Cannabis and cannabis-derived drugs may also help to heal the gut lining.
Research on medications in progress
Many clinical trials have been recently completed or are ongoing for new therapies for Crohn's disease. They include the following:
- Certolizumab is a PEGylated Fab fragment of a humanized anti-TNF alpha monoclonal antibody that was found to have efficacy over placebo in one large trial.
- ABT-874 is a human anti-IL-12 monoclonal antibody being developed by Abbott Laboratories in conjunction with Cambridge Antibody Technology for the treatment of multiple autoimmune diseases including Crohn's disease. Phase II trials have been completed and showed promising results,
- Sargramostim, or granulocyte-monocyte colony stimulating factor (GM-CSF) has been shown to substabtially improve health-related quality of life in pilot studies, measured by an increase in score of a 32-item IBD questionnaire. A recent Phase II trial showed that Sargramostim significantly decreased CD severity (48% compared to 26% placebo group) and improved quality of life (40% versus 19% for placebo).
- Trichuris suis is a pig whipworm that been shown in one study to improve Crohn's disease symptoms.
- Autologous stem cell transplants have also been evaluated.
- Rifabutin, clarithromycin and clofazimine are antibiotics designed to attack mycobacterium avium subsp. paratuberculosis, which may be a cause of Crohn's disease. This treatment, called Myoconda, is being tested by Giaconda.
- Biological therapy for inflammatory bowel disease
- Cholestyramine (Bile acid sequestrant)
- Essential fatty acid interactions
- Crohn's and Colitis Foundation of America - a site with many suggestion on the treatment
- ^ Hanauer SB, Sandborn W (2001). "Management of Crohn's disease in adults" (pdf). Am. J. Gastroenterol. 96 (3): 635–43. doi:10.1111/j.1572-0241.2001.03671.x. PMID 11280528. http://www.ibdforum.com/proto/acghanauer.pdf. Retrieved 2008-02-15.
- ^ Hanauer SB, Strömberg U (2004). "Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials". Clin. Gastroenterol. Hepatol. 2 (5): 379–88. doi:10.1016/S1542-3565(04)00122-3. PMID 15118975.
- ^ Prantera C, Cottone M, Pallone F, et al. (1992). "Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial". Gastroenterology 116 (3): 521–6. doi:10.1016/S0016-5085(99)70172-1. PMID 10029609. .
- ^ a b c Gopal, Latha; Senthil Nachimuthu (2006-05-23). "Crohn Disease". eMedicine. http://www.emedicine.com/MED/topic477.htm. Retrieved 2006-07-02.
- ^ Hanauer SB (1991). "Sulfasalazine vs. steroids in Crohn's disease: David vs. Goliath?". Gastroenterology 101 (4): 1130–1. PMID 1679735.
- ^ a b Greenberg GR, Feagan BG, Martin F, et al. (1994). "Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group". N. Engl. J. Med. 331 (13): 836–41. doi:10.1056/NEJM199409293311303. PMID 8078529.
- ^ Sandborn WJ, Löfberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR (2005). "Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials". Am. J. Gastroenterol. 100 (8): 1780–7. doi:10.1111/j.1572-0241.2005.41992.x. PMID 16086715.
- ^ Steinhart AH, Feagan BG, Wong CJ, et al. (2002). "Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial". Gastroenterology 123 (1): 33–40. doi:10.1053/gast.2002.34225. PMID 12105831. .
- ^ Podolsky, Daniel K. (August 2002). "Inflammatory bowel disease". New England Journal of Medicine 346 (6): 417–29. doi:10.1056/NEJMra020831. PMID 12167685. http://content.nejm.org/cgi/content/extract/347/6/417. Retrieved 2006-07-02.
- ^ Rosenberg JL, Levin B, Wall AJ, Kirsner JB (1975). "A controlled trial of azathioprine in Crohn's disease". Am J Dig Dis 20 (8): 721–6. doi:10.1007/BF01070829. PMID 1098449.
- ^ Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W (2003). "Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease". Aliment. Pharmacol. Ther. 18 (11-12): 1113–20. doi:10.1046/j.1365-2036.2003.01793.x. PMID 14653831.
- ^ Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C (2000). "Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease". Cochrane Database Syst Rev (2): CD000545. doi:10.1002/14651858.CD000545. PMID 10796557.
- ^ Hanauer SB, Korelitz BI, Rutgeerts P, et al. (2004). "Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial". Gastroenterology 127 (3): 723–9. doi:10.1053/j.gastro.2004.06.002. PMID 15362027.
- ^ a b Hanauer SB, Feagan BG, Lichtenstein GR, et al. (2002). "Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial". Lancet 359 (9317): 1541–9. doi:10.1016/S0140-6736(02)08512-4. PMID 12047962.
- ^ Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR et al. (February 2004). "Infliximab maintenance therapy for fistulizing Crohn's disease.". The New England journal of medicine 350 (9): 876–85. doi:10.1056/NEJMoa030815. PMID 14985485.
- ^ Rutgeerts P, Van Assche G, Vermeire S (2006). "Review article: Infliximab therapy for inflammatory bowel disease--seven years on". Aliment. Pharmacol. Ther. 23 (4): 451–63. doi:10.1111/j.1365-2036.2006.02786.x. PMID 16441465.
- ^ Hanauer SB, Sandborn WJ, Rutgeerts P, et al. (2006). "Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial". Gastroenterology 130 (2): 323–33; quiz 591. doi:10.1053/j.gastro.2005.11.030. PMID 16472588.
- ^ "Medication guide: Humira" (pdf). Abbott Laboratories. 2008-02-01. http://www.rxabbott.com/pdf/humira_medguide.pdf. Retrieved 2008-03-25.
- ^ Sandborn WJ, Colombel JF, Enns R, et al. (2005). "Natalizumab induction and maintenance therapy for Crohn's disease". N. Engl. J. Med. 353 (18): 1912–25. doi:10.1056/NEJMoa043335. PMID 16267322.
- ^ Michetti P, Mottet C, Juillerat P, et al. (2007). "Severe and steroid-resistant Crohn's disease". Digestion 76 (2): 99–108. doi:10.1159/000111023. PMID 18239400.
- ^ "FDA Approves Tysabri to Treat Moderate-to-Severe Crohn's Disease". Food and Drug Administration. 2008-01-14. http://www.fda.gov/bbs/topics/NEWS/2008/NEW01775.html. Retrieved 2008-03-09.
- ^ Ghosh S, Goldin E, Gordon F, Malchow H, Rask-Madsen J, Rutgeerts P, Vyhnálek P, Zádorová Z, Palmer T, Donoghue S (2003). "Natalizumab for active Crohn's disease". N. Engl. J. Med. 348 (1): 24–32. doi:10.1056/NEJMoa020732. PMID 12510039.
- ^ Feagan BG, Sandborn WJ, Hass S, Niecko T, White J (2007). "Health-related quality of life during natalizumab maintenance therapy for Crohn's disease". Am. J. Gastroenterol. 102 (12): 2737–46. doi:10.1111/j.1572-0241.2007.01508.x. PMID 18042106.
- ^ Kleinschmidt-DeMasters BK, Tyler KL (2005). "Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis". N. Engl. J. Med. 353 (4): 369–74. doi:10.1056/NEJMoa051782. PMID 15947079.
- ^ Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (2005). "Progressive multifocal leukoencephalopathy in a patient treated with natalizumab". N. Engl. J. Med. 353 (4): 375–81. doi:10.1056/NEJMoa051847. PMID 15947078.
- ^ "Tysabri product information sheet". http://tysabri.com/en_US/tysb/footer/TYSABRI-pi.pdf. Retrieved 2008-03-13. [dead link]
- ^ Hanauer, Stephen B.; Hanauer, Stephen B. (March 1996). "Inflammatory bowel disease". New England Journal of Medicine 334 (13): 841–848. doi:10.1056/NEJM199603283341307. PMID 8596552. http://content.nejm.org/cgi/content/extract/334/13/841. Retrieved 2006-11-10.
- ^ "Surgery for Crohn's Disease". Crohn's and Colitis Foundation of America. March 2006. http://www.ccfa.org/info/surgery/surgerycd. Retrieved 2006-06-08.
- ^ Gottschall, Elaine (1994). Breaking the Vicious Cycle: Intestinal Health Through Diet. Baltimore: Kirkton Press. ISBN 0-9692768-1-8.
- ^ A Belluzzi, C Brignola, M Campieri, A Pera, S Boschi, and M Miglioli (June 1996). "Effect of an Enteric-Coated Fish-Oil Preparation on Relapses in Crohn's Disease" (abstract page). New England Journal of Medicine 334 (24): 1557–60. doi:10.1056/NEJM199606133342401. PMID 8628335. http://content.nejm.org/cgi/content/abstract/334/24/1557?ijkey=6460c4103d06d06d427a2779ed0d755c3a7671cc&keytype2=tf_ipsecsha.
- ^ Croese, J.; O'Neil, J.; Masson, J.; Cooke, S.; Melrose, W.; Pritchard, D.; Speare, R. (2006). "A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors". British Medical Journal 55 (1): 136–7. doi:10.1136/gut.2005.079129. PMC 1856386. PMID 16344586. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1856386. ; lay summary
- ^ Caprilli R, Gassull M, Escher J et al. (2006). "European evidence based consensus on the diagnosis and management of Crohn's disease: special situations". Gut 55 Suppl 1: i36–58. doi:10.1136/gut.2005.081950c. PMC 1859996. PMID 16481630. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1859996.
- ^ a b Joos S, Brinkhaus B, Maluche C, et al. (2004). "Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study". Digestion 69 (3): 131–9. doi:10.1159/000078151. PMID 15114043.
- ^ Gerhardt, H.; Seifert, F.; Buvari, P.; Vogelsang, H.; Repges, R. (2001). "Therapie des aktiven Morbus Crohn mit dem Boswellia-serrata-Extrakt H 15". Zeitschrift für Gastroenterologie 39 (1): 11–17. doi:10.1055/s-2001-10708. PMID 11215357.
- ^ Feagan BG, Fedorak RN, Irvine EJ, et al. (2000). "A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators". N. Engl. J. Med. 342 (22): 1627–32. doi:10.1056/NEJM200006013422202. PMID 10833208.
- ^ Ursing B, Alm T, Bárány F, et al. (1982). "A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result". Gastroenterology 83 (3): 550–62. PMID 6124474.
- ^ Cohen LB (2004). "Re: Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy. Can J Gastroenterol 2004; 18(2): 101-104". Can. J. Gastroenterol. 18 (6): 419; author reply 419. PMID 15230268.
- ^ Cannabis-based drugs could offer new hope for inflammatory bowel disease patients
- ^ Schreiber S, Rutgeerts P, Fedorak R, Khaliq-Kareemi M, Kamm M, Boivin M, Bernstein C, Staun M, Thomsen O, Innes A (2005). "A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.". Gastroenterology 129 (3): 807–18. doi:10.1053/j.gastro.2005.06.064. PMID 16143120.
- ^ Mannon PJ, Fuss IJ, Mayer L, et al. (2004). "Anti-interleukin-12 antibody for active Crohn's disease". N. Engl. J. Med. 351 (20): 2069–79. doi:10.1056/NEJMoa033402. PMID 15537905.
- ^ Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ (2005). "Sargramostim for active Crohn's disease". N. Engl. J. Med. 352 (21): 2193–201. doi:10.1056/NEJMoa041109. PMID 15917384.
- ^ B. Dieckgraefe (2006). "Improving Mucosal Barrier Function - A Novel Therapeutic Strategy for Crohn's Disease". http://www.touchalimentarydisease.com/articles.cfm?article_id=6363&level=2.
- ^ Summers RW, Elliott DE, Urban JF, Thompson R, Weinstock JV (2005). "Trichuris suis therapy in Crohn's disease". Gut 54 (1): 87–90. doi:10.1136/gut.2004.041749. PMC 1774382. PMID 15591509. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1774382.
- ^ Oyama Y, Craig RM, Traynor AE, et al. (2005). "Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease". Gastroenterology 128 (3): 552–63. doi:10.1053/j.gastro.2004.11.051. PMID 15765390.
Inflammatory bowel disease: Crohn's disease and ulcerative colitis Main Anatomical terms History Organizations PeopleList of people diagnosed with Crohn's disease · Deaths from Crohn's disease
Wikimedia Foundation. 2010.